Price
$18.38-4.17%Social Signal Score
Analyst Ratings
11 analysts52-week range
- Last close
- $18.38
- Off 52w high
- -18.2%
- 200-day average
- $11.70
- vs 200-day
- +57.1%
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jonathan E. Lim
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 103
- Beta
- 0.65
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 35.11
Financials
Net Income
$-44.08MEBITDA
$-43.36MFree Cash Flow
$-27.28MEPS (diluted)
$-0.14Shares Outstanding (diluted)
311.34M+161.7%Operating Expenses
$47.62MCash & Debt
$268.74MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-124.55M | $-0.44 |
| 2024 | $0.00 | $-161.65M | $-0.69 |
| 2023 | $0.00 | $-125.04M | $-0.83 |
| 2022 | $0.00 | $-242.81M | $-1.99 |
| 2021 | $0.00 | $-122.76M | $-1.03 |
| 2020 | $0.00 | $-101.66M | $-0.85 |
| 2019 | $0.00 | $-12.04M | $-0.10 |
Valuation
ERAShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
160Social Signal Score
Mentions (11)
- News (RSS)seekingalpha·19h ago·Neutral
Erasca: Revolution's Approval Just Took Risk Out Of The Fast Follower
View source ↗ - Newsseekingalpha.com·23h ago·Positive
Erasca: Revolution's Approval Just Took Risk Out Of The Fast Follower Erasca (ERAS) is now a fully funded fast follower in RAS-targeted oncology, with ~$1B pro forma liquidity and three potential registration-enabling trials ahead. Daraxonrasib's FDA approval validates the RAS mechanism, shifting competition to tolerability and dose intensity, where ERAS-0015 shows potential differentiation. ERAS-0015 demonstrates strong tolerability, no dose-limiting toxicities, and high dose intensity, support…
View source ↗ - Newsglobenewswire.com·14d ago·Positive
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015 New Preclinical PDAC Package for PRP Shows >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Contrasts Mechanism, Breadth, & Development Role Against Erasca's Phase 1 ERAS-0015 Dataset MELBOURNE, Australia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel tre…
View source ↗ - Newsglobenewswire.com·20d ago·Positive
…reported clinical datasets from leading RAS-targeted programs, including Revolution Medicines' daraxonrasib (RASONQUE™; RMC-6236) and Erasca's pan-RAS molecular glue ERAS-0015.
View source ↗ - News (RSS)seekingalpha·20d ago·Positive
Erasca, Inc. (ERAS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Erasca, Inc. (ERAS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Erasca, Inc. (ERAS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium Oral presentation to share updated monotherapy clinical data for ERAS-0015 including additional patients and longer follow-up, expanding on the previously reported preliminary results from the ongoing AURORAS-1 Phase 1 trial Poster presentation to share nonclinical combination data of ERAS-0015 and ERAS-4001 demonstrating synergy in KRAS G12X-driven models SAN DIEGO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Erasca, I…
View source ↗ - News (RSS)yahoo·31d ago·Negative
FDA Fast Track Puts Erasca’s (ERAS) Pancreatic Bet Center Stage
View source ↗ - Newsglobenewswire.com·43d ago·Neutral
Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma Designation follows encouraging Phase 1 activity across multiple tumor types including 2L+ KRAS G12X pancreatic cancer Three potentially registration-enabling trials planned across pancreatic and lung cancers Additional Phase 1 monotherapy and combination data expected in H1 2027 SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-s…
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
Erasca Reports Second Quarter 2026 Business Updates and Financial Results Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination
View source ↗ - Newsbusinesswire.com·57d ago·Negative
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $ERAS--ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with SBS Law.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.14 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.14 vs $-0.11miss
- Mon, May 11$-0.60 vs $-0.11miss
- Thu, Mar 12$-0.10 vs $-0.11beat
- Wed, Nov 12$-0.11 vs $-0.11beat
- Tue, Aug 12$-0.12 vs $-0.12beat
- Tue, May 13$-0.11 vs $-0.12beat
Estimates and results for ERAS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ERAS officers and directors.
- Bought
- $4.6m
- Sold
- $2.3m
9 trades
3 trades
- Garner Ebunsold
- Morris Shannonsold
- Garner Ebunsold
- Casdin Alexander W.bought
- Start Valerie Denise Hardingbought
- Lim Jonathan Ebought
- Lim Jonathan Ebought
- Casdin Alexander W.bought
88 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ERAS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.